WuXi AppTec / WuXi TIDES
WuXi STA's injectable drug product platform lists mRNA/DNA-LNP and end-to-end LNP services, including lipid discovery, formulation and process development, analysis, and manufacturing.
China / United StatesFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
51 matching companies
Crystal NAX
Offers RNA synthesis, LNP / tLNP formulation screening, analytical characterization, and early-stage manufacturing. The website describes manufacturing as GMP-like for preclinical, toxicology, and IND-enabling programs; this should not be equated with full cGMP commercial manufacturing.
United States / ChinaFull profile →
Moderna
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
United StatesFull profile →
BioNTech SE
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
GermanyFull profile →
Arcturus Therapeutics
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
United StatesFull profile →
TriLink BioTechnologies
Active in nucleic acid synthesis since 1996; a Maravai-owned CDMO supplying mRNA, NTPs, and CleanCap capping reagents.
United StatesFull profile →
Acuitas Therapeutics
Founded in 2009, this LNP delivery technology company advances nucleic acid drug delivery R&D and commercialization primarily through partners. Licensed platforms are not classified as company-owned drug candidates.
CanadaFull profile →
Catalent
Public service pages disclose mRNA/saRNA analysis, including IPRP-HPLC, RT-qPCR, cell-free potency assays, and LNP characterization. These disclosures do not establish full mRNA-LNP manufacturing at every site.
United StatesFull profile →
Lonza
Offers mRNA/LNP process and analytical development and clinical and small-scale commercial manufacturing. Geleen integrates RNA and LNP production.
SwitzerlandFull profile →
Evonik
Evonik combines its lipid/LNP development services with ST PHARM's custom nucleic acid capabilities. A partnered supply chain does not mean Evonik manufactures every component itself.
GermanyFull profile →
CureVac
BioNTech announced completion of its CureVac acquisition on 2025-12-18. This record retains CureVac's mRNA technology and historical entity information without treating it as an independent publicly traded company.
GermanyFull profile →
Ethris
Uses mRNA technology to develop respiratory treatments; official disclosures report 2022 financing and a strategic investment from Cipla.
GermanyFull profile →
etherna
Offers mRNA engineering, custom LNPs, and manufacturing technology platforms to support partners from design through production.
BelgiumFull profile →
Abogen Biosciences
Discloses an integrated mRNA/LNP platform. Its lyophilized shingles mRNA vaccine ABO1108 is in Phase 3 in China. The ABO2203 licensing and option agreement with Novartis announced on 2026-10-02 is not classified as financing.
ChinaFull profile →
WestGene Biopharma
Founded in July 2021, the company focuses on innovative mRNA drugs and adjuvants, with oncology, infectious disease, and other mRNA programs.
ChinaFull profile →
RNACure
Founded in 2019, the company discloses mRNA molecular engineering, delivery, and immunomodulation platforms with CMC integrated into technology development.
ChinaFull profile →
Innorna
IN006 is a bivalent RSV vaccine based on the company's mRNA and LNP platforms. The company reported completion of Phase 2 enrollment and vaccination in 2025; IN026 received FDA IND clearance in 2026.
ChinaFull profile →
MediciBIO
Develops gene delivery platforms for mRNA, saRNA, siRNA, and ASOs, along with internal drug programs. In 2026 it announced an LNP platform and Korean-market collaboration with Crystal NAX.
South KoreaFull profile →
ReCode Therapeutics
Develops mRNA and gene correction therapies using tissue-selective LNP delivery. In 2026 it disclosed additional Cystic Fibrosis Foundation support and a cystic fibrosis gene-editing collaboration.
United StatesFull profile →
Cartesian Therapeutics
Develops mRNA cell therapies, with a lead program based on ex vivo mRNA CAR-T. It also collaborates with WestGene on in vivo tLNP delivery; these approaches should be evaluated separately.
United StatesFull profile →
Replicate Bioscience
A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.
United StatesFull profile →
Tiba Biotech
Develops RNA nanodelivery through a non-lipid approach adjacent to LNP technology; it should not be classified as a conventional LNP platform.
United StatesFull profile →
Ziphius
Founded in 2019, the company develops self-amplifying RNA vaccines and therapeutics and LNP platforms.
BelgiumFull profile →
Aldevron
Offers RNA drug substance, LNP encapsulation, analytical testing, and aseptic fill-finish, with disclosed mRNA-LNP manufacturing in one facility under one quality system.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.